17.04.2013 - Danish Santaris Pharma A/S has entered a global strategic R&D collaboration with BristolMyers Squibb in the field of RNA drugs.
Santaris said it will use its Locked Nucleic Acid (LNA) platform to discover and develop new mRNA or microRNA drug candidates. Under the terms of the agreement, the Horsholm-based company will get US$10 upfront and up to US$90m of milestone payments. Furthermore, the drug developer will be eliglible to receive royalties on worldwide sales araising from the alliance.
In successful cases, BMS will gain the exclusive global marketing rights. Further financial details were not disclosed by the companies. Santaris Pharma's LNA platform A/S combines the company's proprietary LNA chemistry with its highly specialised and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including infectious and inflammatory diseases, cardiometabolic disorders, cancer and rare genetic disorders.
RNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates that target previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states
The network will advise SMEs on how to get financial support for projects at a pilot plant in Ghent. This flexible pilot plant will selectively invest in equipment for promising technologies to promote further growth. The partnership will also develop and deliver programmes and tools for training skilled professionals for bio-based industries.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.